Exploring two decades of cancer trends in adolescents and young adults: Insights from a resource-restricted country. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...
Increased Risk of Young-Onset Digestive Tract Cancers Among Young Adults Age 20-39 Years With Nonalcoholic Fatty Liver Disease: A Nationwide Cohort Study Men with untreated mCRPC were randomly ...
FG-3246 (also known as FOR46) is a potential first-in-class fully human antibody-drug conjugate (ADC), exclusively in-licensed from Fortis Therapeutics, and is being developed by FibroGen for ...
FORT MYERS, Fla., Jan. 22, 2026 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) is among the first oncology providers in Florida selected to enroll patients in a phase 3 ...
Clinical and pathologic characteristics of mCRPC were largely similar between younger and older patients. Overall survival was not significantly different between younger and older patients with mCRPC ...
A real-world study found Erleada reduced the risk of death compared with Nubeqa in patients with metastatic ...
BOSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Halda Therapeutics today announced that new clinical data on HLD-0915, the company’s first-in-class oral RIPTAC™ therapeutic, will be presented at the plenary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results